Skip to main content
SpringerLink
Log in

Antithrombin Agents as Adjuncts to Thrombolytic Therapy

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. French JK, Williams BF, Hart HH, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. Br Med J 1996;312:1637–1641.

    Google Scholar 

  2. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S–275S.

  3. Armstrong PW. Heparin in acute coronary disease: Requiem for a heavyweight? [editorial]. N Engl J Med 1997; 337:492–494.

    PubMed  Google Scholar 

  4. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385–391.

    PubMed  Google Scholar 

  5. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995;92:944–949.

    PubMed  Google Scholar 

  6. Gruber A, Harker LA, Hanson SR, Kelly AB, Griffin JH. Antithrombotic effects of combining activated protein C and urokinase in non-human primates. Circulation 1991;84: 2454–2454.

    PubMed  Google Scholar 

  7. Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Res 1989;55:635–643.

    PubMed  Google Scholar 

  8. Lee CD, Mann KG. Activation/inactivation of human coagulation factor V by plasmin. Blood 1989;73:185–190.

    PubMed  Google Scholar 

  9. Eisenberg PR. Role of heparin in coronary thrombolysis. Chest 1992;101(Suppl):131S–139S.

    Google Scholar 

  10. Verheugt FA, Liem A, Zijlstra F, Veen G, Bronzwaer JGF. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: Results of the Heparin in Early Patency (HEAP) pilot study.J Am Coll Cardiol 1998;312:289–293.

    Google Scholar 

  11. Liem A, Zijlstra F, Hoorntje JCA, Suryapranata H, de Boer M-J, Verheugt FWA. Randomised trial of high dose bolus heparin before primary angioplasty in acute myocardial infarction: The Heparin in Early Patency (HEAP) pilot study (abstr). Circulation 1998; (Suppl) 1:767.

  12. Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433–1437.

    PubMed  Google Scholar 

  13. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122–128.

    PubMed  Google Scholar 

  14. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol 1994;24:1445–1452.

    PubMed  Google Scholar 

  15. Col J, Decoster O, Hanique G, et al. Infusion of heparin conjunct to streptokinase accelerates reperfusion of acute myocardial infarction: Results of a double blind randomized study (OSIRIS) (abstr). Circulation 1992;86:I–259.

    Google Scholar 

  16. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65–71.

    Google Scholar 

  17. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770.

    Google Scholar 

  18. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction [review]. N Engl J Med 1997;336:847–860.

    PubMed  Google Scholar 

  19. O'Connor CM, Meese R, Carney R, et al. for the DUCCS Group. A randomized trial of heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: The Duke University Clinical Cardiology Study (DUCCS). J Am Coll Cardiol 1994;23:11–18.

    PubMed  Google Scholar 

  20. Collins R, Conway M, Alexopoulos D, et al. for the ISIS Pilot Study Investigators. Randomised factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J 1987;8:634–642.

    PubMed  Google Scholar 

  21. Topol EJ, Califf RM, Van de Werf F, et al. Perspectives on large-scale cardiovascular clinical trials for the new millenium. Circulation 1997;95:1072–1082.

    PubMed  Google Scholar 

  22. White HD, Cross DB, Elliott JM, Norris RM, Yee TW. Longterm prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994;89:61–67.

    PubMed  Google Scholar 

  23. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993–1003.

    PubMed  Google Scholar 

  24. White HD, Aylward PE, Frey MJ, et al. Randomized, dou-ble-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155–2161.

    PubMed  Google Scholar 

  25. Simes RJ, Topol EJ, Holmes DR, Jr., et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923–1928.

    PubMed  Google Scholar 

  26. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631–1637.

    Google Scholar 

  27. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624–1630.

    PubMed  Google Scholar 

  28. Neuhaus K-L, v.Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994;90:1638–1642.

    PubMed  Google Scholar 

  29. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775–782.

    Google Scholar 

  30. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911–921.

    PubMed  Google Scholar 

  31. Metz BK, White HD, Granger CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO-IIb trial. J Am Coll Cardiol 1998;31:1493–1498.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Green Lane Hospital, Green Lane West, Epsom, Auckland, New Zealand

    John K. French & Harvey D. White

Authors
  1. John K. French
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harvey D. White
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

French, J.K., White, H.D. Antithrombin Agents as Adjuncts to Thrombolytic Therapy. J Thromb Thrombolysis 8, 159–166 (1999). https://doi.org/10.1023/A:1008975216841

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008975216841

Search

Navigation